Delivery Order SPE2DB22D3011-SPE2DB25FQ2EV
- Not listed
- The Defense Logistics Agency awarded a $5,388.87 delivery order to AmerisourceBergen Drug Corp for the supply of MONOVISC 88 mg/4 ml syringes (4 ml quantity) under a firm fixed price contract type. The award, issued on July 23, 2025, with an ultimate completion date of July 24, 2025, represents a non-set-aside, competitively awarded procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this delivery order at its corporate office location in...
- The Defense Logistics Agency awarded a $2,194.02 delivery order to AmerisourceBergen Drug Corp for Monovisc 88 mg/4 mL syringes on August 15, 2025, with an ultimate completion date of August 18, 2025. This is a firm fixed price, non-set-aside contract performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX),...
- The Defense Logistics Agency awarded a delivery order valued at $2,409.96 to AmerisourceBergen Drug Corp for Monovisc 88 mg/4 ml syringes on August 11, 2025, with an ultimate completion date of August 12, 2025. This firm fixed price, non-set-aside contract represents a single delivery order fulfillment under AmerisourceBergen's larger indefinite delivery vehicle with DLA. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $6,708.32 to AmerisourceBergen Drug Corp for the supply of Monovisc 88 mg/4 mL syringes on July 24, 2025, with completion expected by July 25, 2025. This firm fixed price contract represents a non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The product will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania....
- AmerisourceBergen Drug Corp was awarded a $3,443.09 delivery order by the Defense Logistics Agency (DLA) on August 15, 2025, for the supply of Monovisc 88 mg/4 mL syringes. The contract is a firm fixed price delivery order with an ultimate completion date of August 18, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This award represents a non-set-aside, competitively awarded contract, reflecting AmerisourceBergen's demonstrated capability to meet...
- The Defense Logistics Agency awarded a delivery order valued at $9,013.11 to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Monovisc 88 mg/4 ml syringes. The contract is a firm fixed-price delivery order with a completion date of August 6, 2025, and will be performed at the contractor's location in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's capability to compete for federal medical...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $1,227.19 to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation. This delivery order is for the supply of MONOVISC 88 MG/4 ML SYRINGE 4ML, a pharmaceutical product. The delivery order has a period of performance through March 12, 2024. AmerisourceBergen Drug Corp holds an indefinite delivery contract (IDC) awarded by DLA, valued at up to $999,999,999.00 with a performance...
- The Defense Logistics Agency (DLA) awarded a $10,158.47 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Monovisc 88 mg/4 mL syringes. This is a firm fixed-price, competitively awarded contract with no set-aside designation, with performance scheduled for completion by July 29, 2025. The product will be delivered to the Conshohocken, Pennsylvania location, where AmerisourceBergen maintains its corporate headquarters. This delivery order is a child contract issued...
- The Defense Logistics Agency awarded a delivery order valued at $3,757.37 to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Monovisc 88 mg/4 mL syringes. The order, which represents a child contract under a larger indefinite delivery vehicle, is scheduled for completion by July 30, 2025, and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. This award was made on a firm fixed-price basis with no set-aside designation, indicating it was...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Monovisc 88 mg/4 ml syringes. This firm fixed price delivery order, valued at $7,229.88, represents a non-set-aside award and is due for completion by August 13, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. Monovisc is a viscosupplement injection used in orthopedic and...
- SPE2DB22D3011Indefinite Delivery Contract
- SPE2DB22D3011-SPE2DB25FQ2EVDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,096.73 to AmerisourceBergen Drug Corp for the supply of MONOVISC 88 MG/4 ML syringes (4 ML quantity) on August 12, 2025, with a completion date of August 13, 2025. The contract is structured as a firm fixed price delivery order with no set-aside designation, indicating competitive award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, performed the work at its corporate office location in the same municipality. This delivery order is issued under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. The delivery order facilitates the Defense Logistics Agency's medical supply chain operations by providing injectable pharmaceutical products for military and federal healthcare systems. MONOVISC is a hyaluronic acid-based viscosupplement commonly used in orthopedic and rheumatologic applications for joint pain management. AmerisourceBergen Drug Corp's extensive federal contract portfolio demonstrates its established capability as a critical vendor for pharmaceutical procurement, supplying a broad range of medications, vaccines, and medical devices across multiple therapeutic domains to support Department of Defense healthcare requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 8/12/25 |